Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ikechukwu Ibegbu

Gastroenterology Jacksonville, NC Medical Doctor

NPI 1639154248 CMS profile 164340

4 Josh Court, Jacksonville, NC 28546

Open in the dashboard

General payments

$10,203

213 records reported · program years 2019–2025

Research payments

$83,696

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,498,908 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Ikechukwu Ibegbu of Jacksonville, NC is reported in the CMS Open Payments database as having received $10,203 across 213 general payments and $83,696 in research payments paid to them. Separately, studies naming them as principal investigator received $1,498,908 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $813 28
2024 General $380 20
2023 General $224 5
2023 Research $32,410 1
2022 General $693 37
2022 Research $49,608 1
2021 General $1,366 63
2021 Research $1,678 1
2020 General $540 26
2019 General $6,185 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ikechukwu Ibegbu
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Ikechukwu Ibegbu were reported at $813. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Ikechukwu Ibegbu Gastroenterology median Middle half National median
2019 $6,185 $417 $126–$1,100 $163
2020 $540 $224 $74–$624 $114
2021 $1,366 $352 $106–$1,054 $132
2022 $693 $448 $129–$1,270 $149
2023 $224 $533 $150–$1,390 $160
2024 $380 $605 $160–$1,606 $164
2025 $813 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Apollo Endosurgery US Inc $6,021 9 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $599 47 payments
  3. AbbVie, Inc. $500 35 payments
  4. Boston Scientific Corporation $484 5 payments
  5. Palette Life Sciences, Inc. $450 1 payment
  6. Ardelyx, Inc. $338 17 payments
  7. Pfizer Inc. $213 15 payments
  8. Allergan Inc. $200 1 payment
  9. Ironwood Pharmaceuticals, Inc $174 11 payments
  10. Nestle HealthCare Nutrition Inc. $163 10 payments
  11. Other $1,061 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $6,150 2 payments
  2. Food and Beverage $3,786 209 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $200 1 payment
  4. Education $67 1 payment
Products named General payments · program years 2019–2025
  1. Orbera $5,735 3 payments
  2. LINZESS $534 26 payments
  3. SOLESTA $450 1 payment
  4. IBSRELA $338 17 payments
  5. TRULANCE Gastroenterology $242 21 payments
  6. OverStitch Endoscopic Suturing System Endoscopic Tissue Approximation Device $202 3 payments
  7. CREON $199 14 payments
  8. TRULANCE Gastroenterology $198 15 payments
  9. OverStitch Endoscopic Suturing System OverStitch Endoscopic Suturing System_ENDO $196 2 payments
  10. ZENPEP $182 11 payments
  11. Other $2,297 119 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $83,696 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,471

Median for Gastroenterology: 569

Drug cost

$249,542

Median for Gastroenterology: $104,976

Branded share of claims

47%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 122 $99,718
Zenpep Lipase/Protease/Amylase Brand 18 $70,003
Creon Lipase/Protease/Amylase Brand 14 $33,608
Dexlansoprazole Dr Dexlansoprazole Brand 58 $12,927
Mesalamine Generic 30 $10,645
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 252 $4,220
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 21 $3,500
Pantoprazole Sodium Generic 465 $3,205
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 115 $1,897
Dicyclomine Hcl Generic 71 $1,830

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$222,042

Medicare's payments for the services billed

Medicare patients

509

Average age 70

Services billed

1,782

277 women, 232 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 46%
Diabetes 36%
Ischemic heart disease 24%
Chronic kidney disease 21%
Depression 19%
COPD 16%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IBSRELA
  • Ardelyx, Inc. $139
$139 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $52
  • AbbVie, Inc. $16
$68 122 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $50
$50 — —
VELSIPITY
  • PFIZER INC. $26
$26 — —
XELJANZ
  • PFIZER INC. $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

216 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record